Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Researchers Studying Two Point-of-Care Tests to Gauge PGx Response to Anti-Platelet Drugs
August 11, 2010
Spartan Bioscience and Nanosphere are each working with academic research groups to determine the utility of their CYP2C19 tests for gauging response to Plavix at the point of care.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Spartan Bioscience's CE-Marked CYP2C19 Test Will Also Be Submitted to the FDA
December 22, 2010 / Pharmacogenomics Reporter - Canadian Team Validates Spartan's Point-of-Care CYP2C19 Test to Personalize Anti-Platelet Treatment
November 30, 2011 / Pharmacogenomics Reporter - Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option
April 4, 2012 / Pharmacogenomics Reporter - Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 2, 2011 / Pharmacogenomics Reporter - 'Not Approvable' Letter Thwarts Nanosphere's Hopes to Launch FDA-Approved Plavix PGx Test
June 22, 2011 / Pharmacogenomics Reporter